Evaxion announces increased focus and fast-tracking of its new ai discovery to patients

Copenhagen, denmark, march 28, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the discovery and development of ai-powered immunotherapies, today announces an increased focus on its strategy around its core ai capabilities allowing fast and de-risked development of its pipeline.
EVAX Ratings Summary
EVAX Quant Ranking